File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1158/1078-0432.CCR-13-1766
- Scopus: eid_2-s2.0-84903822347
- PMID: 24987108
- WOS: WOS:000338920100006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Infusions of allogeneic natural killer cells as cancer therapy
Title | Infusions of allogeneic natural killer cells as cancer therapy |
---|---|
Authors | |
Issue Date | 2014 |
Citation | Clinical Cancer Research, 2014, v. 20, n. 13, p. 3390-3400 How to Cite? |
Abstract | Natural killer (NK) cells are normal white blood cells capable of killing malignant cells without prior sensitization. Allogeneic NK cell infusions are attractive for cancer therapy because of non-cross-resistant mechanisms of action and minimal overlapping toxicities with standard cancer treatments. Although NK therapy is promising, many obstacles will need to be overcome, including insufficient cell numbers, failure of homing to tumor sites, effector dysfunction, exhaustion, and tumor cell evasion. Capitalizing on the wealth of knowledge generated by recent NK cell biology studies and the advancements in biotechnology, substantial progress has been made recently in improving therapeutic efficiency and reducing side effects. A multipronged strategy is essential, including immunogenetic-based donor selection, refined NK cell bioprocessing, and novel augmentation techniques, to improve NK function and to reduce tumor resistance. Although data from clinical trials are currently limited primarily to hematologie malignancies, broader applications to a wide spectrum of adult and pediatrie cancers are under way. The unique properties of human NK cells open up a new arena of novel cell-based immun otherapy against cancers that are resistant to contemporary therapies. © 2014 American Association for Cancer Research. |
Persistent Identifier | http://hdl.handle.net/10722/294496 |
ISSN | 2023 Impact Factor: 10.0 2023 SCImago Journal Rankings: 4.623 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Leung, Wing | - |
dc.date.accessioned | 2020-12-03T08:22:52Z | - |
dc.date.available | 2020-12-03T08:22:52Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Clinical Cancer Research, 2014, v. 20, n. 13, p. 3390-3400 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294496 | - |
dc.description.abstract | Natural killer (NK) cells are normal white blood cells capable of killing malignant cells without prior sensitization. Allogeneic NK cell infusions are attractive for cancer therapy because of non-cross-resistant mechanisms of action and minimal overlapping toxicities with standard cancer treatments. Although NK therapy is promising, many obstacles will need to be overcome, including insufficient cell numbers, failure of homing to tumor sites, effector dysfunction, exhaustion, and tumor cell evasion. Capitalizing on the wealth of knowledge generated by recent NK cell biology studies and the advancements in biotechnology, substantial progress has been made recently in improving therapeutic efficiency and reducing side effects. A multipronged strategy is essential, including immunogenetic-based donor selection, refined NK cell bioprocessing, and novel augmentation techniques, to improve NK function and to reduce tumor resistance. Although data from clinical trials are currently limited primarily to hematologie malignancies, broader applications to a wide spectrum of adult and pediatrie cancers are under way. The unique properties of human NK cells open up a new arena of novel cell-based immun otherapy against cancers that are resistant to contemporary therapies. © 2014 American Association for Cancer Research. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Cancer Research | - |
dc.title | Infusions of allogeneic natural killer cells as cancer therapy | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-13-1766 | - |
dc.identifier.pmid | 24987108 | - |
dc.identifier.scopus | eid_2-s2.0-84903822347 | - |
dc.identifier.volume | 20 | - |
dc.identifier.issue | 13 | - |
dc.identifier.spage | 3390 | - |
dc.identifier.epage | 3400 | - |
dc.identifier.eissn | 1557-3265 | - |
dc.identifier.isi | WOS:000338920100006 | - |
dc.identifier.issnl | 1078-0432 | - |